Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026

B Pivotal Phase 3 WU-KONG28 Study of ZEGFROVY® selected as Late-Breaking Abstract Oral presentation for DZD6008, the 4th generation EGFR TKI, in EGFR mutated NSCLC…
posteditor
posteditor
Articles: 17424

Other News